Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network
- PMID: 19917596
- PMCID: PMC2806486
- DOI: 10.1176/appi.ajp.2009.09091261
Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network
Abstract
Objective: The purpose of the analysis was to examine the temporal course of improvement in symptoms of posttraumatic stress disorder (PTSD) and substance use disorder among women in outpatient substance abuse treatment.
Method: Participants were 353 women randomly assigned to 12 sessions of either trauma-focused or health education group treatment. PTSD and substance use assessments were conducted during treatment and posttreatment at 1 week and after 3, 6, and 12 months. A continuous Markov model was fit on four defined response categories (nonresponse, substance use response, PTSD response, or global response [improvement in both PTSD and substance use]) to investigate the temporal association between improvement in PTSD and substance use symptom severity during the study's treatment phase. A generalized linear model was applied to test this relationship over the follow-up period.
Results: Subjects exhibiting nonresponse, substance use response, or global response tended to maintain original classification; subjects exhibiting PTSD response were significantly more likely to transition to global response over time, indicating maintained PTSD improvement was associated with subsequent substance use improvement. Trauma-focused treatment was significantly more effective than health education in achieving substance use improvement, but only among those who were heavy substance users at baseline and had achieved significant PTSD reductions.
Conclusions: PTSD severity reductions were more likely to be associated with substance use improvement, with minimal evidence of substance use symptom reduction improving PTSD symptoms. Results support the self-medication model of coping with PTSD symptoms and an empirical basis for integrated interventions for improved substance use outcomes in patients with severe symptoms.
Trial registration: ClinicalTrials.gov NCT00078156.
Comment in
-
Toward an improved model of treating co-occurring PTSD and substance use disorders.Am J Psychiatry. 2010 Jan;167(1):11-3. doi: 10.1176/appi.ajp.2009.09111602. Am J Psychiatry. 2010. PMID: 20068121 Free PMC article. No abstract available.
-
Dazed and confused by self-medication.Am J Psychiatry. 2010 May;167(5):600; author reply 600-1. doi: 10.1176/appi.ajp.2010.10010099. Am J Psychiatry. 2010. PMID: 20439402 Free PMC article. No abstract available.
References
-
- Chilcoat HD, Menard C. In: Epidemiological investigations: comorbidity of posttraumatic stress disorder and substance use disorder, in Trauma and substance abuse: causes, consequences and treatment of comorbid disorders. Ouimette PC, Brown PJ, editors. Washington, DC: American Psychological Association; 2003. pp. 9–28.
-
- Khantzian EJ. Treating Addiction as a Human Process. London: Aronson; 1999.
-
- Khantzian EJ. The ego, the self, and opiate addiction: theoretical and treatment considerations. Int J Psychoanal. 1977;5:189–199. - PubMed
-
- Chilcoat HD, Breslau N. Investigations of casual pathways between PTSD and drug use disorders. Addict Behav. 1998;23:827–840. - PubMed
-
- Dixon L, Haas G, Weiden PJ. Drug abuse in schizophrenia patients: clinical correlates and reasons for use. Am J Psychiatry. 1991;148:224–230. - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- U10 DA013046/DA/NIDA NIH HHS/United States
- U10 DA013035/DA/NIDA NIH HHS/United States
- U10DA13732/DA/NIDA NIH HHS/United States
- U10DA13035/DA/NIDA NIH HHS/United States
- U10DA13714/DA/NIDA NIH HHS/United States
- U10 DA013714/DA/NIDA NIH HHS/United States
- U10DA013046/DA/NIDA NIH HHS/United States
- U10 DA013038/DA/NIDA NIH HHS/United States
- U10DA013720/DA/NIDA NIH HHS/United States
- U10 DA013732/DA/NIDA NIH HHS/United States
- K24 DA022412/DA/NIDA NIH HHS/United States
- K24DA022412/DA/NIDA NIH HHS/United States
- U10DA13038/DA/NIDA NIH HHS/United States
- U10 DA013727/DA/NIDA NIH HHS/United States
- U10 DA013720/DA/NIDA NIH HHS/United States
- U10DA13727/DA/NIDA NIH HHS/United States
